Thread by @KarenMagraith

IMS Congress day 3.
Starting very early with concurrent presentations from menopause societies.
AMS presentation on Menopause and work.
Chaired by Dr Sylvia Rosevear (Aotearoa/NZ). menopause.org.au

I was the first speaker.
Case studies in menopause at work.
I began by acknowledging that some people who experience menopause don’t identify as women. Gender diverse people can also experience menopause.
#IMS2022

Whether a workplace is menopause supportive or not can make the difference between someone staying in their workplace or leaving.

This in turn can have long term impacts including on life trajectory, and retirement income. #IMS2022

Next speaker Prof Martha Hickey. Research findings around menopause at work.#IMS2022

Third speaker A/Prof Amanda Vincent.
Early menopause and work.

Presented Australian research looking at vocational outcomes for women with early menopause and POI. #IMS2022

Next session. Plenary lecture.
Prof Pauline Maki. (USA)
The science of brain fog at menopause. #IMS2022

Objectively measured hot flushes are associated with greater brain white matter hyperintensities. #IMS2022

Does estrogen treatment affect cognition in women with VMS?
We don’t know.

(I’m surprised that this clinically relevant question hasn’t been addressed in research)
#IMS2022

Menopausal factors including estradiol, VMS, sleep and mood can all affect verbal memory dysfunction.

Insufficient evidence to recommend estrogen for dementia prevention. #IMS2022

Next speaker. A/Prof Ada Cheung (Australia).
Transgender health and the impact of aging and menopause. #IMS2022

Discrimination due to trans status. #IMS2022

Concern about VTE risk in trans women using estrogen.

Bone density. Predominately an issue for trans women. Lifestyle recommendations important.
#IMS2022

Paucity of data about the experience of trans people at menopause.
Most trans people taking hormones expect to take GAHT indefinitely.

Feminizing therapy: Transdermal estrogen generally recommended as people age.

Masculinizing GAHT associated with inc risk of MI relative to cisgender women.

Further research needed to guide how to manage GAHT with aging. #IMS2022